Adams Street Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mineralys Therapeutics
MLYS
|
+$40.7M |
| 2 |
HCP
HashiCorp, Inc. Class A Common Stock
HCP
|
+$1.73M |
| 3 |
Advanced Drainage Systems
WMS
|
+$571K |
| 4 |
Freshworks
FRSH
|
+$155K |
| 5 |
CFLT
Confluent
CFLT
|
+$232 |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GitLab
GTLB
|
+$7.34M |
| 2 |
TransDigm Group
TDG
|
+$5.85M |
| 3 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
+$2.2M |
| 4 |
ACLX
Arcellx
ACLX
|
+$1.19M |
| 5 |
Nu Holdings
NU
|
+$1.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 73.77% |
| 2 | Healthcare | 20.44% |
| 3 | Industrials | 5.79% |
| 4 | Financials | 0% |
Similar funds
Adams Street Partners's Q1 2023 Portfolio in Review
As of Q1 2023, Adams Street Partners held 20 positions worth $321M, up 6.9% from $300M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Adams Street Partners deployed $24.5M of net new capital in Q1 2023, opening 4 new positions and adding to 1 existing holding. Its largest new stake was Mineralys Therapeutics: 2,419,501 shares worth $37.9M.
By sector, the portfolio is most concentrated in Technology at 74% of assets, down from 78% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was Icosavax, Inc. Common Stock, an estimated $2.2M trimmed.
- Adams Street Partners's largest Q1 2023 buy was Mineralys Therapeutics: 2,419,501 shares worth $37.9M.
- Adams Street Partners added most to Confluent in Q1 2023, an estimated $232 increase.
- Adams Street Partners's biggest Q1 2023 reduction was Icosavax, Inc. Common Stock, cutting an estimated $2.2M.
- Adams Street Partners fully exited GitLab in Q1 2023, selling an estimated $7.34M.
- Adams Street Partners's ten largest holdings make up 100% of its $321M portfolio in Q1 2023.
- Adams Street Partners opened 4 new positions and closed 7 in Q1 2023.
- Adams Street Partners's portfolio value rose 6.9% quarter-over-quarter to $321M.
Based on Adams Street Partners's 13F filing for Q1 2023, filed 15 May 2023.